A federal jury in Delaware put US biotech major Amgen (Nasdaq: AMGN) on the hook Thursday for at least $271.2 million in ...

Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market Jury awarded ...

In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

A non-statin lipid-lowering agent (e.g., ezetimibe, evolocumab, alirocumab, inclisiran, bempedoic acid) is recommended for patients already on maximally tolerated statin who have a low-density ...

JE: We are excited to rapidly progress towards initial results from our ongoing phase 3 program (ODYSSEY) with our investigational PCSK9-inihibitor alirocumab. "PCSK9 inhibition represents an ...

A non-statin lipid-lowering agent (e.g., ezetimibe, evolocumab, alirocumab, inclisiran, bempedoic acid) is recommended for patients already on maximally tolerated statin who have a low-density ...

That included Sanofi and Regeneron’s rival PCSK9 inhibitor Praluent (alirocumab), which reached the US market shortly after Repatha in 2015. The ruling could effectively put an end to attempts ...

The consensus among analysts is that 'Revenues- Praluent (alirocumab)- US' will reach $57.71 million. The estimate points to a change of -17.6% from the year-ago quarter. Analysts' assessment ...

In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment TARRYTOWN, N.Y. and PARIS, April 18 ...